Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors

Completed · Phase 1

Conditions studied: Unspecified Childhood Solid Tumor, Protocol Specific

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of combining carboplatin and irinotecan in treating children who have refractory solid tumors.

Key facts

Study ID

NCT00024284

Run by

Bristol-Myers Squibb

Starts

2001-06-01

Expected to finish

2003-12-01

Last updated by the study team

2013-04-05

Who can join

Age: 1 and older, up to 21. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Arizona Cancer Center — Tucson, Arizona, United States
• Children's National Medical Center — Washington D.C., District of Columbia, United States
• Washington University Medical Center — St Louis, Missouri, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• Children's Hospital of Pittsburgh — Pittsburgh, Pennsylvania, United States
• St. Jude Children's Research Hospital — Memphis, Tennessee, United States
• Hospital for Sick Children — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.